Faye Adams | Free Lance writer
ATTR- CM Patient-Columnist

Faye Adams, Free Lance writer, ATTR- CM Patient-Columnist

I am first and foremost a wife to the love of my life and a mama to two incredible teenage boys. I am a sister, a daughter, an aunt, and a friend. Those roles are the most important parts of who I am — and how I want to be remembered.   I am also living with hereditary ATTR amyloidosis, the same disease that took my dad’s life in 2010.   Amyloidosis affects my heart, my stomach, and my nerves. There is no cure yet — at least not here on earth — but there are treatments that can slow the progression. I am currently on medication, doing everything I can to fight back. Still, this disease has a way of reminding me that it doesn’t always follow the rules.   When people ask what amyloidosis is, I explain it this way: our bodies make a protein in the liver. Mine misfolds. Instead of working the way it should, it turns into a sticky, glue-like substance that travels through my body and settles in my organs and nerves. Over time, that “glue” makes things harder for my body to function the way it was designed to.   I live daily with the reality of a progressive, life-limiting disease — but I also live with purpose.   I advocate because my dad didn’t have the treatment options I do. I advocate because too many people go undiagnosed for far too long. I advocate because research matters, awareness matters, and patient voices matter.   This diagnosis is part of my story, but it is not the whole story. I am still raising my boys. I am still loving my husband. I am still showing up. I am still fighting.   And I will continue to use my voice until there is a cure. Thank you for walking this road with me.

Appearances:



Day 2 - World Orphan Drug Congress USA 2026 @ 14:00

Beyond Awareness: Translating Lived Experience into Regulatory Evidence

The rare disease ecosystem is undergoing a strategic shift from general awareness to actionable 

advocacy. While patient voices are increasingly invited into drug development, regulators and HTA 

bodies still struggle to translate lived experience into recognized evidence. 

This panel examines how specialized rare disease media—specifically Rare Disease 

Advisor—transforms patient narratives into actionable “human data.” Through curated patient 

columns, RDA creates a validated, public record of patient-reported outcomes that informs endpoint 

development, supports PFDD initiatives, and shortens the diagnostic odyssey. Panelists will explore 

how media can serve as a strategic partner in clinical development, regulatory decision-making, and 

early disease recognition. 

last published: 11/Mar/26 19:05 GMT

back to speakers

Get Involved At World Orphan Drug Congress USA

 

Connect with us

 
 
 

 

To Sponsor Or Exhibit

 
 

Jack Rendell
jack.rendell@terrapinn.com
t/ +44 07577689029

 

 

 

To Speak

 
 

Kaylee Nguyen
kaylee.nguyen@terrapinn.com
 

 

 

 

Marketing & Press

 
 

Jasper Cameron
jasper.cameron@terrapinn.com